Changing trends in the biopharma sector may mean new risks for established players and opportunities for growth, says BIA ...

China’s National Medical Products Administration (NMPA) has granted approval for four-weekly intravenous (IV) maintenance ...

NewCo’ licensing of clinical candidates is allowing Chinese biotechs to offload costs while expanding profits on a global ...

As CF treatment duration extends, registry-based analyses will need to track pathogen-specific trends and long-term disease ...

Genmab has signed an agreement to buy all shares of Merus at $97 per share, in an all-cash transaction valued at $8bn.

Oral liquid drugs play a vital role for patients who have difficulty swallowing tablets and for those requiring personalised ...

The US FDA has expanded the approval of Regeneron Pharmaceuticals' fully human monoclonal antibody, Evkeeza (evinacumab-dgnb) ...

Amgen has revealed a significant investment plan, earmarking $650m to enhance its manufacturing operations in the US.

After demonstrating that its gene therapy can slash Huntington's disease progression by 75%, Uniqure will now file for ...

Evaxion’s preclinical asset targets an unknown infectious disease in which there are no other vaccines available.

Lilly has received approval from the US Food and Drug Administration (FDA) for Inluriyo (imlunestrant) to treat advanced ...

More than two-thirds – 67% - of first responders organisations have deployed new cybersecurity protections in the last 12 ...